Is structure Therapeutics a good stock to buy?

Structure Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings. Structure Therapeutics has only been the subject of 3 research reports in the past 90 days. Read more about Structure Therapeutics' stock forecast and price target.

Should you buy structure Therapeutics (GPCR) stock?

There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GPCR shares. View GPCR analyst ratings or view top-rated stocks. What is Structure Therapeutics' stock price target for 2024? 6 brokers have issued 12-month price objectives for Structure Therapeutics' shares.

Who invests in structure Therapeutics?

Top institutional investors include Janus Henderson Group PLC (4.45%), Price T Rowe Associates Inc. MD (3.35%), Capital Research Global Investors (3.28%), RA Capital Management L.P. (3.24%), Capital International Investors (2.75%) and Bellevue Group AG (0.78%). How do I buy shares of Structure Therapeutics?